☆ 4.7 Article

Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab

RHEUMATOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Rheumatology

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Richard A. Furie et al.

Summary: This study compared the efficacy of obinutuzumab with standard therapies and placebo in the treatment of LN. The results showed that obinutuzumab achieved better complete renal responses at 52 and 104 weeks compared to standard therapies alone. It also showed improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria. Obinutuzumab was well tolerated and no new safety signals were identified.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Hematology

How should we use convalescent plasma therapies for the management of COVID-19?

Erica M. Wood et al.

Summary: Convalescent plasma from blood donors with antibodies to SARS-CoV-2 may benefit COVID-19 patients by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal characteristics, transfusion volume, and administration timing remain to be determined, requiring international collaborative efforts to establish clinical efficacy. Preliminary safety data for COVID-19 CP is encouraging, with ongoing large, high-quality randomized trials starting to report preliminary results.

BLOOD (2021)

Add to Collection

Review Rheumatology

COVID-19 vaccination and antirheumatic therapy

Jack Arnold et al.

Summary: This article discusses the impact of immunosuppressive therapy on COVID-19 vaccination, proposing a suggestion to temporarily suspend treatment to improve vaccine effectiveness, and urging decisions on withholding immunosuppressive therapy to be made in advance without sufficient data support.

RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Brad H. Rovin et al.

Summary: This study evaluated the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing a superior complete renal response rate with voclosporin in combination with MMF and low-dose steroids compared to MMF and low-dose steroids alone. The safety profile was comparable between the two groups. This finding represents an important advancement in the treatment of patients with active lupus nephritis.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab

Sabih Ul Hassan et al.

FRONTIERS IN MEDICINE (2020)

Add to Collection

Meeting Abstract Rheumatology

BLISS-LN: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS

R. Furie et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

Add to Collection

Review Rheumatology

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

Antonis Fanouriakis et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

Add to Collection

Article Rheumatology

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab

Eric F. Morand et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

Add to Collection

Review Hematology

A tale of two antibodies: obinutuzumab versus rituximab

Ciara L. Freeman et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Rheumatology

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

Venkat Reddy et al.

RHEUMATOLOGY (2017)

Add to Collection

Article Rheumatology

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus

Md Yuzaiful Md Yusof et al.

ANNALS OF THE RHEUMATIC DISEASES (2017)

Add to Collection

Article Rheumatology

Responses to Rituximab Suggest B Cell-Independent Inflammation in Cutaneous Systemic Lupus Erythematosus

Edward M. Vital et al.

ARTHRITIS & RHEUMATOLOGY (2015)

Add to Collection

Article Rheumatology

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

Eduardo F. Mysler et al.

ARTHRITIS AND RHEUMATISM (2013)

Add to Collection

Review Immunology

B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress

Md Yuzaiful Md Yusof et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2013)

Add to Collection

Article Rheumatology

B Cell Biomarkers of Rituximab Responses in Systemic Lupus Erythematosus

Edward M. Vital et al.

ARTHRITIS AND RHEUMATISM (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.